Abstract
INTRODUCTION
Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are treatment modalities for coronary revascularization in patients with ischaemic heart disease. Previously, CABG was the standard of care for patients with multivessel disease (MVD), but the introduction of bare metal stents (BMS) and drug-eluting stents (DES) led to the increased use of PCI [1] .
During the past 2 decades, several randomized clinical trials compared the outcomes of CABG versus PCI in patients with stable MVD, with the use of balloon angioplasty (BA), BMS and contemporary DES [2] . Before the availability of DES, meta-analyses compared the survival rates of CABG versus PCI but lacked important information on the incidence of major adverse cardiac and cerebrovascular events (MACCE) [3] . A recent meta-analysis of 6 randomized contemporary trials comparing CABG versus DES in patients with MVD demonstrated that, at 1 year, PCI compared to CABG was associated with a significantly higher incidence of repeat revascularization (RR), a lower stroke rate, and no difference in the incidence of death or myocardial infarction (MI), but no data were provided on the in-hospital and 30-day (early) MACCE rates of either revascularization strategy [4] .
Recent studies indicate that the long-term outcome of surgical revascularization is improved by the use of multiarterial (MultArt) CABG [5] , but this strategy is used relatively infrequently in Europe and the USA [6] .
We analysed the early MACCE outcome of patients at our clinic undergoing surgical or PCI for MVD over 2 decades, evaluated the impact of surgical revascularization with MultArt on early MACCE, and compared these outcomes with those from evolving PCI treatments.
METHODS
This study reviews early outcomes of 12 615 consecutive patients with MVD who underwent isolated primary coronary revascularization with CABG (n = 6667) or PCI (n = 5948) from 1 January 1993 to 31 December 2009. We previously described the longterm survival rates of these patients [7] . Patients undergoing CABG received left internal mammary artery/saphenous vein grafts (LIMA/SV subgroup; n = 5712) or MultArt grafts, involving the LIMA and, in addition, either the right internal mammary artery (85%) and/or the radial artery (27%) with or without the additional use of saphenous vein grafts (MultArt subgroup; n = 955). Priority was given to the use of bilateral internal mammary arteries as in situ grafts. Subgroups of patients having PCI were treated with BA (n = 1020), BMS (n = 3242) and DES (n = 1686) (Supplementary Material, Fig. S1 ).
The analysis does not include patients undergoing concomitant cardiac surgical procedures, those with prior CABG, patients with single-vessel disease or coronary anomalies, and patients with acute MI. We also excluded patients undergoing PCI within 7 days before CABG or with prior PCI. We analysed only the first eligible revascularization record for each patient.
Terms and data collection
The study was approved by the Mayo Clinic institutional review board. The methods of data collection and data definitions (ACC and STS) were described previously [7] .
Follow-up information was obtained through telephone calls and questionnaires mailed to patients at regular intervals and through review of patients' clinical charts supplemented by information from the Social Security Death Index and Accurint V R . The outcomes measured were early mortality, stroke, MI, RR and overall early MACCE (see Supplementary Material, Definitions).
Statistical analysis
Descriptive statistics for categorical variables are reported as frequency and percentage; continuous variables are reported as mean ± standard deviation (SD) and median. Categorical variables were compared between 2 groups with Fisher's exact test when the number of expected events was <5 in any group. v 2 test was used if there were 5 or more expected events in any group. Continuous variables are reported as the mean ± SD and the median and were compared with 2-sample t-test if the data had approximately normal distribution or with Wilcoxon rank sum test if not.
In the unmatched population, multivariable logistic regression models were used to evaluate the impact of CABG versus PCI on early postoperative outcomes after adjusting for baseline variables. A multivariable model was fit for the outcome early MACCE first; all the significant baseline variables were then also included in multivariable models for other outcomes to be consistent (baseline variables are reported in Supplementary Material, Table S1 ). Propensity score matching was done between CABG versus (i) BA, (ii) BMS and (iii) DES; between PCI versus (i) MultArt and (ii) LIMA/SV; and between MultArt versus LIMA/SV separately and one at a time. For example, a propensity score was used to match MultArt patients to PCI patients on the propensity for having PCI. For each case, a control subject was randomly selected from the potential pool of control subjects without replacement, with the restriction that they have similar propensity scores (similar defined as within 0.25 times the SD of the propensity scores). The propensity for PCI was estimated using a logistic regression model with the response variable being PCI. The independent variables used for propensity score calculation included age, gender, body mass index, hypertension, diabetes mellitus, chronic lung disease, renal failure, peripheral arterial disease, previous MI, congestive heart failure, previous cerebrovascular disease, left main coronary disease, 2-vessel coronary disease, 3-vessel coronary disease, priority status of the procedure and the date of the procedure. In the matched samples, P-values comparing the baseline and outcome variables were results from conditional logistic regression. When comparison of baseline variables between matched groups showed significant statistical differences, multivariable models were used to compare the outcome while adjusting for the unbalanced baseline variable. All statistical tests were 2-sided, with the a level set at 0.05 for statistical significance. All statistics were conducted with SAS, version 9.4 (SAS institute, Cary, NC, USA)
RESULTS
Baseline characteristics of patients treated with CABG, the 2 surgical subgroups and PCI are shown in Supplementary Material, Table S1 . There were significant differences between the unmatched groups. Patients undergoing MultArt were generally younger and had significantly less comorbidity but more left main coronary and 3-vessel disease than patients with PCI.
Unadjusted analysis
The unadjusted early MACCE rate was significantly lower for CABG than for PCI (4.1% vs 8.5%, P < 0.001) and lower for MultArt (1.5%) than for LIMA/SV (4.5%, P < 0.001) and PCI (8.5%, P < 0.001). Stroke and early death rates were higher in CABG versus PCI (2.3% vs 0.4%, P < 0.001 and 1.5% vs 1.0%, P = 0.010, respectively), whereas MI and RR rates were lower (0.6% vs 6.0% and 0.3% vs 2.3%, P < 0.001, respectively). Stroke and early death rates were similar in MultArt (0.6% and 0.5%) and PCI (0.4% and 1.0%) and lower than those for LIMA/SV (2.6% and 1.7%, P < 0.001); MI and RR rates were similar in patients having MultArt (0.4% and 0.6%) and LIMA/SV (0.3% and 0.3%) and lower than those having PCI (6.0% and 2.3%, P < 0.001).
Matched analysis
Patients in the 3 PCI subgroups were matched with patients undergoing CABG (Table 1) , and patients in the 2 CABG subgroups were matched with patients treated with PCI (Table 2) . In these matched cohorts, CABG significantly improved the early MACCE rate compared with BA (4.7% vs 13.2%, P < 0.001), BMS (4.3% vs 8.3%, P < 0.001) and DES (2.9% vs 5.5%, P = 0.008) (Fig. 1) . The rate of early MACCE was improved with LIMA/SV versus PCI (4.6% vs 9.2% P < 0.001) and with MultArt versus PCI (1.8% vs 7.8%, P < 0.001) (Fig. 2) . Of note, the rate of stroke was not different with MultArt versus PCI (0.8% vs 0.3%, P = 0.18), but significantly higher with LIMA/SV versus PCI (2.3% vs 0.4%, P < 0.001). The rates for RR with PCI were higher compared with those for MultArt (1.4% vs 0.4%, P = 0.067), and significantly higher compared with those for LIMA/SV (2.4% vs 0.4%, P < 0.001). There were no statistical differences in rates noted between the matched MultArt versus LIMA/SV groups (Table 3 ). In the multivariable model adjusting for the baseline variables with slight differences between matched groups, the results remained similar.
Univariable logistic regression analysis
To evaluate whether the use of MultArt contributed to the reduced risk of early MACCE, we first analysed the groups using the univariable logistic regression model. Many risk factors were identified as predicting early MACCE in our model because of the large cohort. Early MACCE were significantly lower in the CABG and MultArt subgroups compared with PCI and each PCI subgroup (P < 0.001). All variables significantly associated with early MACCE in univariable analysis were entered into multivariable analyses.
Multivariable logistic regression analyses
Estimated odds ratios (ORs) for MI and for RR were significantly higher in patients who had PCI versus MultArt; 13.0 [95% confidence interval (CI): 4.78-35.2; P < 0.001], and 6.96 (95% CI: 2.16-22.4; P = 0.001), respectively, and in PCI versus LIMA/SV, 12.0 (95% CI: 8.26-17.86; P < 0.001) and 9.62 (95% CI: 5.41-17.0; P < 0.001), respectively. ORs for stroke were significantly lower in PCI versus LIMA/SV, 0.17 (95% CI, 0.10-0.28; P < 0.001) and in PCI versus MultArt, 0.29 (95% CI: 0.11-0.74; P = .001), whereas ORs for early death were similar in PCI versus MultArt, 0.81 (95% CI: 0.31-2.11; P = 0.66) but lower compared to LIMA/SV, 0.66 (95% CI: 0.45-0.98; P = 0.038).
The estimated OR for early MACCE following PCI compared with CABG was 2.35 (95% CI: 1.96-2.82; P < 0.001). The estimated ORs for early MACCE were significantly higher following PCI, 4.53 (95% CI: 2.62-7.83; P < 0.001) and LIMA/SV, 2.04 (95% CI: 1.18-3.53; P = 0.011) compared with MultArt. Of note, the use of PCI was also associated with a significantly increased OR, 2.22 (95% CI: 1.85-2.66; P < 0.001) for early MACCE compared with the LIMA/SV group (Supplementary Material, Table S2 ).
DISCUSSION
We report early MACCE outcomes from a large tertiary practice involving a large volume of patients with MVD undergoing isolated primary revascularization over 2 decades. CABG with LIMA to the left anterior descending coronary artery was associated with an improved early MACCE rate compared with revascularization with PCI, including the outcomes of patients receiving DES. Moreover, the addition of 1 or more arterial grafts to bypass the Table 1 : Characteristics of matched patients undergoing coronary artery bypass grafting or percutaneous coronary intervention with balloon angioplasty, bare metal stent or drug- non-left anterior descending coronary vessels improved the overall early MACCE rate beyond that seen with a single arterial graft.
Over the past 2 decades, multiple clinical trials have compared the outcomes of PCI versus CABG, and the results were mainly focused on longer term outcomes [8] . In the Synergy Between PCI with Taxus and Cardiac Surgery (SYNTAX) trial, early MACCE rates were not significantly different between PCI and CABG, both during the hospital stay and at 30 days after the procedure. Of note, there were no data provided on the contribution of individual components to the total early MACCE, but the majority of MACCE occurred during the first 6 months post-procedure, and most cases of stent thrombosis occurred within 30 days after the procedure [9, 10] . In addition, there was no stratification of the CABG cohort into surgical subgroups.
The recent Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial reported that within 30 days after the procedure, PCI and CABG had similar early MACCE rates, with no difference in the frequency of death and MI, but a higher stroke rate with CABG, and higher RR rates with PCI. The higher relative risk of stroke with CABG was evident only early in the post-procedural period [11] . Data were taken from 3 separate propensity score models: PCI versus MultArt: n = 714 patients/group; LIMA/SV versus MultArt: n = 886 patients/group and PCI versus LIMA/SV: n = 2289 patients/group. Importantly, the observation that CABG is associated with an increased risk of stroke has been reported in most studies comparing PCI versus CABG [12] . In our study, patients undergoing LIMA/SV had a significantly increased early stroke rate compared to matched patients treated with PCI, but the risk of early stroke was not significantly increased in matched patients undergoing MultArt compared to patients treated with PCI. This finding may be related to fewer aortic manipulations and a lower number of proximal anastomoses performed during MultArt [13] .
In addition, our report shows that the benefits of CABG and MultArt in the reduction of early MACCE were driven largely by reductions in the rates of both MI and RR. RR was substantially more common after PCI than CABG, with a progressive decline in ORs from the BA era to the BMS era and to the DES era, and consistent with previous observations [14] .
Interestingly, our results correlate with the results of the recent controlled Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease (BEST) trial. In the BEST trial, although the rate of the composite safety end point of death, MI or stroke did not differ significantly between PCI and CABG, the rates of spontaneous MI and RR were significantly greater with PCI than with CABG, and those differences emerged very early and continued to increase throughout the 2-year follow-up period. Importantly, the rate of stroke was not significantly different between PCI and CABG, a finding that contrasts with the results of previous randomized trials. The authors suggest that this finding may be related to the increased use of off-pump CABG (64.3%), which can avoid excessive aortic manipulation and contribute to a reduced rate of stroke in their CABG group. Of note, in our study, the rate of offpump CABG was low (4.2%). However, in the BEST trial, the number of grafted vessels was overall 3.1 ± 0.9, with 2.1 ± 1.1 arterial grafts and only 1.0 ± 0.8 vein grafts per patient [15] . This finding supports our hypothesis that less aortic manipulation and fewer proximal anastomoses performed during MultArt may lower the risk of embolic stroke [16] .
Furthermore, in most of the aforementioned randomized clinical trials, the inclusion of patients was highly selective and did not represent the broader population of patients with MVD undergoing revascularization. The present study included all consecutively treated patients with MVD, aside from those undergoing revascularization for acute MI, which may reflect routine clinical practice more accurately [17] .
Some clinicians believe that the only advantage of a complex MultArt operation is improved long-term survival, but our study suggests that a short-term benefit is reduced early MACCE [18] . As previously shown, the MACCE components do not carry equal weight in a composite end point from the patient's perspective. The risk of stroke was found to be a very important outcome, second only to death, whereas MI and RR had lower relative weights [19] . In the present study, MultArt had a relatively low risk of stroke, not significantly different from PCI, which may be important for clinicians and patients in weighing treatment options.
MultArt appears to confer improved long-term survival [20] . In our practice, the mean annual rate ± SD of MultArt during the study period was 15.2% ± 5.7%, markedly higher than the annual rate reported in the USA and Europe [21] . The interim analyses of the Arterial Revascularization Trial (ART) at 5 years of follow-up reveal that a follow-up period shorter than 8-10 years (when progressive failure of saphenous vein grafts peaks) incompletely depicts the advantages of MultArt [22] .
Further, the currently observed short-term advantage combined with the mounting evidence of the improved long-term outcome of MultArt suggests that its use should be defined as a quality metric for CABG operations, just as the use of LIMA to bypass the left anterior descending coronary artery became a measure of a surgeon's performance [23] . Importantly, the recent guidelines of the European Society of Cardiology/European Association for Cardio-Thoracic Surgery on myocardial revascularization, although discussing the apparent advantages of MultArt, do not highlight any potential differences in early MACCE between the various methods of revascularization [24] .
Limitations
Our study is observational and retrospective and has its inherent limitations. In addition to the potentially confounding selection bias for different procedures, additional concerns include changes in technology, operator skills and concomitant associated medical therapies evolving over a 20-year period. There is also a potential for bias due to unmeasured confounders. However, when we used multivariable models to account for all known differences between the 2 large cohorts, we found a strong independent lower early MACCE advantage associated with MultArt. These results were confirmed by propensity score matched analysis. Our study lacks information on completeness of revascularization and on severity of disease as reflected in the SYNTAX score. However, patients undergoing MultArt and CABG had increased severity of coronary disease reflected by more left main and 3-vessel disease than patients treated with PCI. Our investigation did not analyse separately the outcomes of different generations of DES or of the second arterial conduit used for MultArt, but multivariable analyses showed that the date of the procedure did not influence the difference observed in early MACCE rates among the groups.
CONCLUSION
In conclusion, among patients with MVD who underwent coronary revascularization during the last 20 years, surgical revascularization with MultArt conferred a lower rate of early MACCE compared with PCI. Our results strongly recommend a marked increase in the use of MultArt. In future studies comparing PCI and CABG, MultArt should be the standard for surgical revascularization.
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